A Coronavirus Vaccine Project Takes a Page From Gene Therapy

The approved gene therapies that use adeno-associated viruses are Luxturna, for a form of hereditary blindness, and Zolgensma, for a lethal nerve disease, spinal muscular atrophy. The price of Luxturna is $425,000 per eye. It is made and sold in the United States by Spark Therapeutics, and sold overseas by Novartis. Zolgensma, made by Novartis, is given to young children as a one-time injection, at a price of $2.1 million.

Article source: https://www.nytimes.com/2020/05/04/health/gene-therapy-harvard-coronavirus.html